These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

18 related articles for article (PubMed ID: 8261671)

  • 1. Phorbol myristate acetate (PMA) reverses inhibition of interleukin-2 production by T lymphocytes of patients with systemic lupus erythematosus.
    Sierakowski S; Kucharz EJ
    Med Interne; 1988; 26(1):67-73. PubMed ID: 3261032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced CD3-mediated T lymphocyte proliferation in patients with systemic lupus erythematosus.
    Stekman IL; Blasini AM; Leon-Ponte M; Baroja ML; Abadi I; Rodriguez MA
    Arthritis Rheum; 1991 Apr; 34(4):459-67. PubMed ID: 1826426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responsiveness of systemic lupus erythematosus T cells to signals provided through LCA T200 (CD45) and T1 (CD5) antigens.
    Martorell J; Font J; Rojo I; Vilella R; Ingelmo M; Vives J
    Clin Exp Immunol; 1989 Nov; 78(2):172-6. PubMed ID: 12412744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired T-cell activation in patients with systemic lupus erythematosus.
    Sierakowski S; Kucharz EJ; Lightfoot RW; Goodwin JS
    J Clin Immunol; 1989 Nov; 9(6):469-76. PubMed ID: 2517125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of phorbol myristate acetate on T cell colony formation, interleukin-2 (IL-2) receptor expression and IL-2 production by cells from patients at all stages of HIV infection.
    Allouche M; Lunardi-Iskandar Y; Varela-Millot C; Itzhaki M; Cornuet P; Meyer P; Jasmin C; Georgoulias V
    Clin Exp Immunol; 1990 Aug; 81(2):200-6. PubMed ID: 1696861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T lymphocytes from patients with systemic lupus erythematosus show increased response to interleukin-2 after costimulation with OKT3 monoclonal antibody and phorbol esters.
    Blasini AM; Stekman IL; Gonzalez F; Tositti ML; Rodriguez MA
    Clin Immunol Immunopathol; 1994 Jan; 70(1):66-72. PubMed ID: 8261671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE.
    Tsokos GC; Nambiar MP; Tenbrock K; Juang YT
    Trends Immunol; 2003 May; 24(5):259-63. PubMed ID: 12738420
    [No Abstract]   [Full Text] [Related]  

  • 8. T cells as therapeutic targets in SLE.
    Crispín JC; Kyttaris VC; Terhorst C; Tsokos GC
    Nat Rev Rheumatol; 2010 Jun; 6(6):317-25. PubMed ID: 20458333
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.